Stock listing
NASDAQ:EDSA Edesa Biotech, Inc. Stock
Home listing (NASDAQ) of Edesa Biotech, Inc.
Follow Edesa Biotech, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:EDSA
$2.00 USD -0.06 (-2.9%)
Close on Nov 20, 2026
- Day range
- $1.97 – $2.18 USDNov 20, 2026
- Volume
- 120,961 sharesNov 20, 2026
- Market cap
- $27.02M USDAt the close on Nov 20, 2026 · price × 13.51M shares outstanding
- 52-week range
- $0.72 – $20.32 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $3.57M USDMedian day 43,997 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:EDSA · Home | $2.00 USD | -0.06 (-2.9%) | 120,961 | $2.16 | $2.179 | $1.965 | $2.06 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:EDSA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.00 | -0.06 | -2.9% | $2.16 | $2.179 | $1.965 | 120,961 | |
| $2.06 | +0.10 | +5.1% | $2.12 | $2.206 | $1.99 | 279,309 | |
| $1.96 | +0.07 | +3.7% | $1.86 | $2.05 | $1.85 | 324,012 | |
| $1.89 | -0.05 | -2.6% | $1.94 | $2.00 | $1.735 | 472,413 | |
| $1.94 | -0.14 | -6.7% | $1.96 | $2.02 | $1.76 | 507,554 | |
| $2.08 | -0.14 | -6.3% | $2.13 | $2.349 | $1.99 | 513,003 | |
| $2.22 | +0.20 | +9.9% | $2.11 | $2.31 | $1.851 | 1,004,859 | |
| $2.02 | -0.47 | -18.9% | $2.31 | $2.34 | $1.85 | 2,111,297 | |
| $2.49 | +0.35 | +16.4% | $3.47 | $3.93 | $2.38 | 83,891,233 | |
| $2.14 | +0.01 | +0.5% | $2.12 | $2.20 | $2.01 | 37,762 | |
| $2.13 | -0.04 | -1.8% | $2.14 | $2.179 | $2.10 | 33,588 | |
| $2.17 | -0.11 | -4.8% | $2.38 | $2.38 | $2.15 | 43,997 | |
| $2.28 | -0.16 | -6.6% | $2.49 | $2.49 | $2.244 | 51,200 | |
| $2.44 | -0.13 | -5.1% | $2.57 | $2.61 | $2.40 | 44,785 | |
| $2.57 | -0.13 | -4.8% | $2.86 | $2.86 | $2.558 | 30,628 | |
| $2.70 | +0.14 | +5.5% | $2.55 | $2.82 | $2.55 | 43,636 | |
| $2.56 | -0.07 | -2.7% | $2.64 | $2.64 | $2.485 | 70,684 | |
| $2.63 | +0.04 | +1.5% | $2.62 | $2.72 | $2.57 | 25,665 | |
| $2.59 | -0.18 | -6.5% | $2.71 | $2.74 | $2.545 | 63,800 | |
| $2.77 | +0.01 | +0.4% | $2.71 | $2.918 | $2.67 | 18,142 | |
| $2.76 | -0.09 | -3.2% | $2.89 | $2.99 | $2.749 | 22,690 | |
| $2.85 | +0.03 | +1.1% | $2.87 | $2.93 | $2.70 | 39,305 | |
| $2.82 | +0.04 | +1.4% | $2.81 | $3.025 | $2.81 | 35,515 | |
| $2.78 | +0.21 | +8.2% | $2.57 | $2.918 | $2.57 | 25,039 | |
| $2.57 | -0.10 | -3.7% | $2.68 | $2.77 | $2.52 | 64,000 | |
| $2.67 | +0.02 | +0.8% | $2.62 | $2.79 | $2.54 | 75,800 | |
| $2.65 | -0.20 | -7.0% | $2.84 | $2.84 | $2.62 | 72,600 | |
| $2.85 | -0.09 | -3.1% | $2.89 | $3.09 | $2.82 | 59,700 | |
| $2.94 | -0.57 | -16.2% | $3.56 | $3.56 | $2.87 | 81,600 | |
| $3.51 | -0.15 | -4.1% | $3.61 | $3.76 | $3.49 | 36,500 | |
| $3.66 | -0.24 | -6.2% | $3.96 | $3.96 | $3.66 | 51,400 | |
| $3.90 | +0.18 | +4.8% | $3.77 | $4.01 | $3.77 | 20,100 | |
| $3.72 | -0.19 | -4.9% | $3.91 | $4.00 | $3.72 | 12,800 | |
| $3.91 | +0.05 | +1.3% | $3.80 | $4.22 | $3.80 | 69,900 | |
| $3.86 | -0.15 | -3.7% | $4.01 | $4.01 | $3.81 | 18,400 | |
| $4.01 | -0.20 | -4.8% | $4.15 | $4.16 | $3.91 | 15,500 | |
| $4.21 | +0.65 | +18.3% | $3.57 | $4.27 | $3.51 | 84,600 | |
| $3.56 | -0.09 | -2.5% | $3.59 | $3.73 | $3.47 | 41,200 | |
| $3.65 | -0.36 | -9.0% | $4.04 | $4.04 | $3.64 | 48,200 | |
| $4.01 | -0.02 | -0.5% | $4.04 | $4.10 | $3.97 | 15,500 | |
| $4.03 | +0.06 | +1.5% | $3.90 | $4.15 | $3.90 | 19,600 | |
| $3.97 | -0.10 | -2.5% | $4.02 | $4.09 | $3.97 | 25,500 | |
| $4.07 | -0.04 | -1.0% | $4.02 | $4.20 | $4.02 | 26,000 | |
| $4.11 | -0.03 | -0.7% | $4.17 | $4.24 | $3.99 | 42,000 | |
| $4.14 | 0.00 | 0.0% | $4.03 | $4.14 | $4.01 | 41,400 | |
| $4.14 | +0.27 | +7.0% | $3.93 | $4.20 | $3.91 | 24,800 | |
| $3.87 | -0.25 | -6.1% | $4.08 | $4.12 | $3.84 | 94,400 | |
| $4.12 | -0.02 | -0.5% | $4.18 | $4.35 | $4.06 | 35,000 | |
| $4.14 | -0.09 | -2.1% | $4.28 | $4.44 | $4.03 | 54,200 | |
| $4.23 | -0.43 | -9.2% | $4.70 | $4.84 | $4.23 | 26,500 | |
| $4.66 | -0.06 | -1.3% | $4.80 | $4.90 | $4.64 | 40,200 | |
| $4.72 | -0.01 | -0.2% | $4.79 | $5.10 | $4.72 | 32,000 | |
| $4.73 | 0.00 | 0.0% | $4.69 | $4.91 | $4.69 | 32,000 | |
| $4.73 | -0.03 | -0.6% | $4.72 | $4.97 | $4.72 | 36,400 | |
| $4.76 | 0.00 | 0.0% | $4.74 | $4.87 | $4.69 | 26,200 | |
| $4.76 | -0.02 | -0.4% | $4.81 | $5.05 | $4.76 | 29,800 | |
| $4.78 | +0.04 | +0.8% | $4.78 | $5.01 | $4.61 | 24,100 | |
| $4.74 | +0.12 | +2.6% | $4.70 | $4.94 | $4.45 | 91,700 | |
| $4.62 | +0.02 | +0.4% | $4.65 | $4.93 | $4.50 | 70,600 | |
| $4.60 | -0.34 | -6.9% | $4.97 | $4.98 | $4.60 | 81,200 | |
| $4.94 | +0.49 | +11.0% | $4.50 | $5.10 | $4.40 | 234,800 | |
| $4.45 | +0.05 | +1.1% | $4.39 | $4.75 | $4.28 | 112,000 | |
| $4.40 | -0.03 | -0.7% | $4.45 | $4.60 | $4.12 | 101,500 | |
| $4.43 | -0.33 | -6.9% | $4.50 | $4.95 | $4.17 | 156,200 | |
| $4.76 | -0.99 | -17.2% | $5.19 | $6.00 | $4.50 | 391,900 |
Splits
4 splits since 2015 · NASDAQ:EDSA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-7 | Consolidation | |
| 1-for-6 | Consolidation | |
| 1-for-7 | Consolidation | |
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:EDSA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 17, 2026
Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 27 slides
Latest news
Edesa Biotech Granted Orphan Designation for Paridiprubart for the Treatment of ARDS by the European Commission
Nov 17, 2026
Closed $1.96 (+3.7%) on Nov 17, 2026
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
Nov 9, 2026
Closed $2.49 (+16.4%) on Nov 9, 2026
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
Nov 4, 2026
Closed $2.13 (-1.8%) on Nov 5, 2026
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Oct 15, 2026
Closed $2.67 (+0.8%) on Oct 15, 2026
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Aug 19, 2026
Closed $4.76 (-17.2%) on Aug 20, 2026
Edesa Biotech Announces Proposed Public Offering
Aug 19, 2026
Closed $4.76 (-17.2%) on Aug 20, 2026
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Aug 13, 2026
Closed $5.35 (-1.5%) on Aug 14, 2026
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Jun 11, 2026
Closed $5.65 (+8.4%) on Jun 11, 2026
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Jun 5, 2026
Closed $5.46 (-23.0%) on Jun 5, 2026
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference
May 19, 2026
Closed $11.95 (+32.8%) on May 19, 2026
Edesa Biotech, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 16 in the last 12 months · 105 in all · newest Nov 17, 2026 · oldest 2019
- Decks
- 15 decks · latest October 2026
Where Edesa Biotech, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:EDSA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:EDSA | BOATS | United States | USD |
| Tradegate:RBT | Tradegate | Germany | EUR |
Valuation
Price/book 3.1× against a median of 1.9×: 8th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $16.72M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 3.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Edesa Biotech, Inc. · NASDAQ:EDSA | US$27.02M | US$16.72M | n/a | n/a | n/a | 3.1× | n/a | 0.0× | 0.47 |
| Holy Stone Healthcare Co., Ltd. · TPEX:4194 | US$27.49M | US$25.08M | n/a | n/a | n/a | 7.3× | n/a | 0.0× | n/a |
| SoftOx Solutions AS · OSL:SOFTX | US$27.28M | US$25.25M | n/a | n/a | n/a | 11.6× | n/a | 0.0× | n/a |
| Amplia Therapeutics Ltd. · ASX:ATX | US$26.84M | US$8.63M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Nasus Pharma Ltd. · AMEX:NSRX | US$26.82M | US$15.11M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | 0.99 |
| Telomir Pharmaceuticals, Inc. · NASDAQ:TELO | US$26.82M | US$22.30M | n/a | n/a | n/a | 6.1× | n/a | 0.0× | 1.74 |
| Aprogen, Inc · KRX:007460 | US$26.80M | US$21.45M | n/a | 0.2× | n/a | 0.6× | −60.1% | 0.6× | n/a |
| BriaCell Therapeutics Corp · TSX:BCT | US$26.79M | US$6.25M | n/a | n/a | n/a | 1.7× | n/a | 0.0× | 1.07 |
| Alterity Therapeutics Ltd. · ASX:ATH | US$26.76M | US$2.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | n/a |
| EyePoint, Inc. · NASDAQ:EYPT | US$26.65M | −US$72.44M | n/a | −28.1× | n/a | 0.3× | n/a | 0.2× | 1.36 |
| PolTREG Spolka Akcyjna · GPW:PTG | US$26.08M | US$22.35M | n/a | 378× | n/a | 2.2× | n/a | 0.1× | n/a |
| Median of the others | US$26.81M | US$18.28M | 0.2× | 1.9× | −60.1% | 0.0× | 1.22 |
Forecasts
2 strong buy · Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.33 USD · Analysts' mean
- EPS, year to Sep 2026
- -1.99 · 3 analysts
Team and board
| Officer | Role |
|---|---|
| Par Nijhawan | Chief Executive Officer |
| Peter J. Weiler | Chief Financial Officer |
| Michael Brooks | President |
| Blair Gordon | Vice President, Research and Development |
| Gary Koppenjan | Vice President, Corporate Affairs |
Events
- Next results
- Dec 11, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Aug 13, 2026 · After close | −1.5% |
| Q2 2026 | May 14, 2026 · After close | −10.7% |
| Q1 2026 | Feb 13, 2026 · After close | +1.0% |
| Q4 2025 | Dec 12, 2025 | −17.5% |
| Q3 2025 | Aug 8, 2025 · After close | −0.5% |
| Q2 2025 | May 14, 2025 · After close | −1.5% |
| Q1 2025 | Feb 14, 2025 · After close | −7.1% |
| Q4 2024 | Dec 13, 2024 · After close | −2.1% |
| Q3 2024 | Aug 9, 2024 · After close | −4.8% |
| Q2 2024 | May 10, 2024 · After close | −3.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Feb 9, 2024 · After close | +7.9% |
| Q4 2023 | Dec 15, 2023 · After close | −7.5% |
| Q3 2023 | Aug 9, 2023 · After close | −3.3% |
| Q2 2023 | May 11, 2023 · After close | −7.4% |
| Q1 2023 | Feb 10, 2023 · After close | −2.8% |
| Q4 2022 | Dec 16, 2022 · Before open | −1.0% |
| Q3 2022 | Aug 12, 2022 · After close | −4.8% |
| Q2 2022 | May 13, 2022 · Before open | +1.1% |
| Q1 2022 | Feb 14, 2022 · Before open | −2.1% |
| Q4 2021 | Dec 28, 2021 · After close | −2.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 27 slides | October 2026 |
| Investor Presentation (August 2026) | Investor deck | 27 slides | August 2026 |
| ATS 2026 | Conference | 10 slides | May 20, 2026 |
| Investor Presentation (May 2026) | Investor deck | 10 slides | May 15, 2026 |
| Investor Presentation (November 2025) | Investor deck | 21 slides | Nov 17, 2025 |
| Investor Presentation (July 2024) | Investor deck | 41 slides | July 2024 |
| Investor Presentation (May 2024) | Investor deck | 41 slides | May 2024 |
| Investor Presentation (April 2024) | Investor deck | 39 slides | April 2024 |
| Investor Presentation (January 2024) | Investor deck | 46 slides | January 2024 |
| Investor Presentation (November 2021) | Investor deck | 36 slides | November 2021 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2021) | Investor deck | 35 slides | Mar 22, 2021 |
| Investor Presentation (January 2021) | Investor deck | 27 slides | Jan 4, 2021 |
| Investor Presentation (October 2020) | Investor deck | 28 slides | October 2020 |
| Investor Presentation (September 2020) | Investor deck | 26 slides | September 2020 |
| Investor Presentation (September 2019) | Investor deck | 19 slides | September 2019 |
Financings
| Raise | Date |
|---|---|
| Public offering of common shares (or pre-funded warrants) and accompanying common share warrants Announced: about US$25M · US$5.5 a share · Warrants at US$7.5 · Guggenheim Securities Dealers: Guggenheim Securities (lead) Use of proceeds: General corporate purposes, possibly including working capital, capital expenditures, and research, development and manufacturing expenses | Aug 20, 2026 |
| Private placement of common shares Announced: about US$3.5M · US$4.69 a share Buyers: Chief Executive Officer of Edesa (common shares at $5.21 per common share) Insiders: Edesa's Chief Executive Officer is an investor in the PIPE, buying at $5.21 per common share Use of proceeds: Advancing the vitiligo program and paridiprubart, plus working capital and general corporate purposes | Jun 11, 2026 |
| At-the-market programme of common shares Tranche closed: US$3.4M raised | Dec 12, 2025 |
| Private placement of series B-1 convertible preferred shares and common shares Closed: US$15M raised · US$1.92 a share Buyers: Velan Capital (led the placement); Nantahala Capital; Rubric Capital Management LP; Stonepine Capital Management; Broadfin Holdings LLC Insiders: Officers and directors purchased approximately $1.1 million of the securities sold Use of proceeds: Advance EB06 CXCL10 antibody into a Phase 2 study in nonsegmental vitiligo, plus working capital and general corporate purposes | Feb 13, 2025 |
| Private placement of securities Closed: US$1.5M raised Buyers: Entity affiliated with Edesa's Chief Executive Officer and Founder ($1.5 million in gross proceeds under a securities purchase agreement) Insiders: An entity affiliated with the Chief Executive Officer and Founder provided the $1.5 million under a securities purchase agreement | Dec 13, 2024 |
| At-the-market programme of common shares Tranche closed: US$600,000 raised | Dec 13, 2024 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 328.8K | 0 | 211.8K | 228.3K | 1.27M | ||||
| Cost of revenue | 0 | 17.6K | 0 | 133.3K | 250.0K | 818.6K | ||||
| Gross profit | 0 | 311.2K | 0 | 78.5K | -21.8K | 453.1K | ||||
| Research and development | 3.67M | 2.88M | 4.79M | 13.3M | 17.9M | 3.33M | 1.08M | 2.09M | 1.97M | 1.73M |
| Operating income | -7.91M | -7.01M | -9.22M | -18.4M | -23.7M | -6.40M | -1.62M | -5.08M | -5.22M | -4.91M |
| Depreciation and amortization | 119.3K | 186.0K | 183.5K | 118.2K | 118.8K | 57.6K | 1.66K | 188.0K | 179.3K | 149.6K |
| EBITDA | -7.79M | -6.83M | -9.04M | -18.3M | -23.6M | -6.34M | -1.62M | -4.89M | -5.05M | -4.76M |
| Income before tax | -7.18M | -6.17M | -8.37M | -17.5M | -13.3M | -6.36M | -5.04M | -5.03M | -5.02M | |
| Income tax | 800 | 800 | 800 | 800 | 800 | 800 | 0 | 800 | 800 | 7.20K |
| Net income | -7.19M | -6.17M | -8.37M | -17.5M | -13.3M | -6.36M | -1.54M | -5.04M | -5.03M | -5.03M |
| Earnings per share, basic | -1.27 | -1.93 | -2.93 | -7.37 | -1.10 | -0.74 | -0.47 | -1.76 | -3.44 | -0.57 |
| Earnings per share, diluted | -1.10 | -0.74 | -0.47 | -1.76 | -3.44 | -0.57 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 10.8M | 1.00M | 5.40M | 7.09M | 7.84M | 7.21M | 3.37M | 3.73M | 4.57M | 7.42M |
| Short-term investments | 1.60M | 6.08M | 1.99M | 3.99M | ||||||
| Receivables | 3.30M | 87.4K | 7.34K | 41.2K | 1.29K | 85.8K | ||||
| Inventory | 0 | 224.3K | 68.1K | 249.4K | ||||||
| Current assets | 11.5M | 1.68M | 6.44M | 9.09M | 12.1M | 8.10M | 3.39M | 10.7M | 6.76M | 12.1M |
| Property, plant and equipment | 0 | 8.70K | 12.7K | 15.0K | 14.8K | 7.39K | 1.06M | 879.5K | 756.1K | |
| Total assets | 13.5M | 3.81M | 8.89M | 11.6M | 14.6M | 10.8M | 3.40M | 11.8M | 7.72M | 12.9M |
| Current liabilities | 1.08M | 1.83M | 1.82M | 2.14M | 1.46M | 1.53M | 183.8K | 493.4K | 320.9K | 623.6K |
| Total liabilities | 1.83M | 1.84M | 2.18M | 1.53M | 1.65M | |||||
| Shareholders' equity | 12.5M | 1.98M | 7.05M | 9.39M | 13.1M | 6.63M | 3.21M | 3.55M | 7.40M | 12.3M |
| Shares outstanding | 7.14M | 3.25M | 3.08M | 2.38M | 13.3M | 9.62M | 3.24M | 5.33M | 1.50M | 10.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -7.32M | -4.89M | -6.64M | -12.3M | -13.7M | -4.99M | -1.29M | -4.62M | -4.70M | -4.51M |
| Capital spending | 0 | -5.66K | -6.15K | -4.86K | -6.87K | -382.8K | -302.7K | -402.3K | ||
| Free cash flow | -6.64M | -12.3M | -13.7M | -4.99M | -1.30M | -5.00M | -5.00M | -4.91M | ||
| Cash from investing | 0 | -5.66K | -6.15K | 19.1K | -6.87K | -4.47M | 1.69M | 557.4K | ||
| Cash from financing | 17.0M | 592.0K | 4.83M | 11.6M | 14.2M | 7.09M | 8.77M | 0 | 7.31M | |
| Change in cash | 9.75M | -4.32M | -1.73M | -748.3K | 625.6K | 2.18M | -1.63M | -345.4K | -2.85M | 3.46M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 17, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Material contract | SEC |
| 4 · Change in ownership | Nov 5, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 4, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 23, 2026 | Management or board change | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 25, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 25, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Aug 20, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Aug 20, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Aug 19, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jul 14, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Jul 13, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| S-3 · Registration statement | Jul 2, 2026 | Offer document | SEC |
| D | Jun 26, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Jun 18, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jun 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Material contract | SEC |
| 8-K · Current report | Jun 5, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 29, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 29, 2026 | Offer document | SEC |
| 8-K · Current report | May 29, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 10, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 3, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 3, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 3, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 16, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 5, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 3, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 2, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 2, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 2, 2026 | Insider trade | SEC |
| 8-K · Current report | Feb 24, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 13, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 12, 2025 | Current report | SEC |
| 424B5 · Prospectus | Dec 12, 2025 | Offer document | SEC |
| 10-K · Annual report | Dec 12, 2025 | Annual report | SEC |
| 8-K · Current report | Dec 12, 2025 | Results | SEC |
| 4 · Change in ownership | Dec 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2025 | Current report | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 30, 2025 | Material contract | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Sep 10, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 9, 2025 | Current report | SEC |
| 424B5 · Prospectus | Sep 9, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Sep 5, 2025 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2025 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Jul 30, 2025 | Other filings | SEC |
| S-3 · Registration statement | Jul 25, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 2, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 28, 2025 | Offer document | SEC |
| 8-K · Current report | May 28, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2025 | Results | SEC |
| 4 · Change in ownership | May 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 2, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 4, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 4, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 4, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 4, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Mar 12, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Mar 11, 2025 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 4, 2025 | Other filings | SEC |
| S-3 · Registration statement | Mar 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Mar 3, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Feb 26, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 25, 2025 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 20, 2025 | Other filings | SEC |
| 3 · Initial statement of ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 18, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| D | Feb 14, 2025 | Other filings | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 14, 2025 | Results | SEC |
| 8-K · Current report | Feb 13, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Dec 20, 2024 | Annual report | SEC |
| 10-K · Annual report | Dec 13, 2024 | Annual report | SEC |
| 8-K · Current report | Dec 13, 2024 | Results | SEC |
| 4 · Change in ownership | Dec 3, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 1, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Oct 4, 2024 | Offer document | SEC |
| 8-K · Current report | Oct 4, 2024 | Material contract | SEC |
| 4 · Change in ownership | Oct 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2024 | Current report | SEC |
| 4 · Change in ownership | Jun 4, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jun 3, 2024 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | May 31, 2024 | Offer document | SEC |
| 8-K · Current report | May 30, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 10, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2024 | Results | SEC |
| 4 · Change in ownership | May 1, 2024 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 5, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 5, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 5, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 25, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 9, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 10-K · Annual report | Dec 15, 2023 | Annual report | SEC |
| 8-K · Current report | Dec 15, 2023 | Results | SEC |
| 8-K · Current report | Oct 26, 2023 | Current report | SEC |
| 8-K · Current report | Oct 23, 2023 | Material contract | SEC |
| 8-K · Current report | Oct 12, 2023 | Material contract | SEC |
| 8-K · Current report | Oct 11, 2023 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 21, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 4, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jul 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 21, 2023 | Insider trade | SEC |
This page holds 200 of 759 filings. Open Filings
Cap table
Built by 6ix from Edesa Biotech, Inc.’s releases · as of Aug 20, 2026
- Common shares
- 13,511,531
- Fully diluted
- 13,511,531
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,511,531 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,511,531 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Charles V Olson Other companies: Anthera Pharmaceuticals Inc (Chief Technology Officer · Jan 5, 2016 – May 20, 2017 · Past) | Director · Since at least Dec 8, 2016 |
| Blair Gordon | Vice President, Research and Development · Since at least Nov 4, 2026 |
| David Louis Hill | Director · Dec 20, 2016 – Mar 12, 2019 · Past |
| Frank R Oakes | Director · Mar 12, 2018 – Jul 20, 2023 · Past |
| Gary Koppenjan | Vice President, Corporate Affairs · Since at least Aug 20, 2026 |
| Gregory T Baxter | EVP, Corporate Development · Mar 28, 2017 – Mar 12, 2018 · Past |
| Joan Chypyha | Director · Since at least May 23, 2023 |
| Kathi Niffenegger | Chief Financial Officer · Sep 1, 2014 – Nov 2, 2022 · Past |
| Lorin K Johnson | Director · Oct 13, 2020 – Feb 28, 2022 · Past |
| Michael Brooks | President · Since at least Jun 7, 2019 |
All 14 people
| Person | Seat |
|---|---|
| Par Nijhawan | Chief Executive Officer · Since at least Oct 15, 2026 |
| Peter J Weiler | Chief Financial Officer · Since at least May 1, 2025 |
| Peter J. Weiler | Chief Financial Officer · Since at least May 29, 2026 |
| Stephen Lemieux | Chief Financial Officer · Jul 15, 2023 – Aug 4, 2023 · Past |
Log in to ask 6ix AI your own questions about Edesa Biotech, Inc.